New drug aims to tame blood vessel inflammation without steroids

NCT ID NCT05380453

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug secukinumab (Cosentyx) in 151 adults with newly diagnosed giant cell arteritis, a condition causing inflamed blood vessels. Participants were in remission and received either secukinumab or a placebo, along with a steroid taper. The goal was to see if secukinumab could delay or prevent disease relapse, allowing patients to use less steroids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: secukinumab (Cosentyx)
What this could lead to: If successful, this could offer a new treatment option to control giant cell arteritis and reduce reliance on steroids.
What could go wrong: This is a completed Phase 3 trial, but results are not yet public. The drug may not prevent relapse better than placebo, and side effects like infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arteritis Giant Cell Arteritis polymyalgia rheumatica temporal arteritis vascular disorder vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIANT CELL ARTERITIS

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site

Würzburg, Bavaria, 97080, Germany
Novartis Investigative Site

Göttingen, Lower Saxony, 37075, Germany
Novartis Investigative Site

Düsseldorf, North Rhine-Westphalia, 40225, Germany
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Jena, Thuringia, 07740, Germany
Novartis Investigative Site

Bad Abbach, 93077, Germany
Novartis Investigative Site

Bad Nauheim, 61231, Germany
Novartis Investigative Site

Berlin, 12161, Germany
Novartis Investigative Site

Berlin, 12435, Germany
Novartis Investigative Site

Berlin, 13125, Germany
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Cologne, 51149, Germany
Novartis Investigative Site

Dresden, 01067, Germany
Novartis Investigative Site

Erlangen, 91054, Germany
Novartis Investigative Site

Gommern, 39245, Germany
Novartis Investigative Site

Hanover, 30625, Germany
Novartis Investigative Site

Herne, 44649, Germany
Novartis Investigative Site

Ludwigshafen, 67063, Germany
Novartis Investigative Site

Mainz, 55131, Germany
Novartis Investigative Site

Minden, 32429, Germany
Novartis Investigative Site

München, 81667, Germany
Novartis Investigative Site

Rendsburg, 24768, Germany
Novartis Investigative Site

Sendenhorst, 48324, Germany
Novartis Investigative Site

Trier, 54292, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.